MISSISSAUGA, ON, July 24, 2024 /CNW/ - Kye Pharmaceuticals, Inc. ("Kye"), a commercial-stage biopharmaceutical company focused on identifying, licensing, and commercializing novel medicines for patients in Canada, today announced that it has entered into a License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals Inc. ("Catalyst"), securing exclusive Canadian commercial rights to AGAMREE® (vamorolone), an novel corticosteroid for the treatment of Duchenne Muscular Dystrophy ("DMD"). Under the terms of the agreement, Catalyst will supply the product to Kye, who will assume full responsibility for obtaining regulatory approval for AGAMREE for the treatment of DMD from Health Canada and all future aspects of commercialization of the product within Canada. Kye currently markets FIRDAPSE® in Canada, Catalyst's flagship product for the treatment of Lambert Eaton myasthenic syndrome.
Read more at newswire.caKye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.